Xeris Biopharma Holdings, Inc. (XERS)

NASDAQ: XERS · USD

$10.6

+0.19 (+1.8%)· Recorded snapshot

Market cap	1.9B
Revenue (ttm)	335.4M
Net income (ttm)	-17.2M
EPS (ttm)	-$0.10
Shares out	182.3M
P/E (forward)	70.3x
Volume	1,199,422
Beta	0.84

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 335.4M
Net income (ttm): -17.2M
EPS (ttm): -$0.10
P/E (forward): 70.3x
Market cap: 1.9B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantener

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E70.3

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROIC8.8

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All XERS indicators

Market & fundamental data

Available fields

223

Groups with data

Currency

USD

Showing 223 of 223 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001867096
Company name	Xeris Biopharma Holdings, Inc.
Country	United States
Country code	US
CUSIP number	98422E103
Earnings date	2026-11-05
Earnings time	bmo
Employees	435
Employees change	41
Employees growth	10.41%
Enterprise value	$2.1B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2005
In index	RUSSELL2000
Industry	Drug Manufacturers - Specialty & Generic
IPO date	2018-06-21
Is primary listing	Yes
Is SPAC	No
ISIN number	US98422E1038
Last 10-K release date	2026-03-02
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$1.9B
Market cap category	Small-Cap
Next earnings date	2026-11-05
Options	Yes
Price	$10.64
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	XERS
U.S. state	Illinois
Website	https://www.xerispharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	156.01x
Earnings yield	-0.96%
EV/EBIT	58.09x
EV/EBITDA	43.59x
EV/FCF	38.19x
EV/Sales	6.34x
FCF / EV yield	2.62%
FCF yield	2.84%
Forward EV/Sales	4.91x
Forward P/E	70.27x
Forward P/S	4.53x
Industry forward P/E	13.87x
Industry P/E	173.94x
P/(FCF - SBC) ratio	71.08x
P/(OCF - SBC) ratio	68.74x
P/FCF ratio	35.17x
P/OCF ratio	34.59x
P/S ratio	5.84x
Price/EBITDA ratio	40.15x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	10.91%
EBITDA margin	14.54%
FCF margin	16.6%
Gross margin	86.58%
Operating margin	10.91%
Pretax margin	-5.12%
Profit margin	-5.12%
Profit per employee	$-39,460
Profitable years	1
Revenue per employee	$771,067
ROA	6.13%
ROA (5Y)	-10.92%
ROCE	16.46%
ROIC	8.84%
SBC / revenue	8.38%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
FCF growth (QoQ)	-15.62%
Gross profit growth	43.52%
Gross profit growth (Q)	33.45%
Gross profit growth 3Y	38.35%
Gross profit growth 5Y	67.12%
Net income growth years	4
OCF growth (Q)	4,440.11%
OCF growth (QoQ)	-16.28%
Operating income growth (Q)	15.42%
Revenue growth	36.33%
Revenue growth (Q)	28.74%
Revenue growth (QoQ)	10.79%
Revenue growth 3Y	35.75%
Revenue growth 5Y	58.32%
Revenue growth quarters	27
Revenue growth years	9

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-938,000
Depreciation and amortization	$12.2M
EBIT	$36.6M
EBITDA	$48.8M
EPS	$-0.10
FCF per share	$0.31
Financing cash flow	$6.7M
Free cash flow	$55.7M
Free cash flow minus SBC	$27.5M
Gross profit	$290.4M
Investing cash flow	$-938,000
Net cash flow	$62.4M
Net income	$-17.2M
Operating cash flow minus SBC	$28.5M
Operating income	$36.6M
Revenue	$335.4M
Stock-based compensation	$28.1M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	0.6
Book value per share	$-0.06
Debt / EBITDA	5.1
Debt / FCF	5.2
Goodwill	$22.9M
Interest coverage	1.3
Long-term assets	$137.1M
Long-term liabilities	$232.1M
Net cash (debt)	$-167.7M
Net cash / market cap	-8.56%
Net debt / EBITDA	3.44
Net debt / FCF	3.01
Piotroski F-Score	6
Property, plant and equipment	$26.6M
Shareholders' equity	$-9.7M
Tangible book value	$-115.3M
Tangible book value per share	$-0.66
Total assets	$411.9M
Total cash	$121.7M
Total debt	$289.4M
Total liabilities	$421.6M
WACC	8.71%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.9
Current assets	$274.8M
Current liabilities	$189.6M
Current ratio	1.45
Inventory turnover	0.61
Net working capital	$33.5M
Quick ratio	0.95
Working capital	$85.2M
Working capital turnover	3.82

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-10.29%
Dividend yield	0%
Shareholder yield	-10.29%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$7.76
1D price change	1.82%
1M price change	17.31%
1M total return	17.31%
1W price change	-4.09%
1W total return	-4.09%
1Y price change	14.66%
1Y return CAGR	14.67%
1Y total return	14.66%
20-day SMA	$10.27
200-day SMA	$7.47
3M price change	30.02%
3M total return	30.02%
3Y price change	563.04%
3Y return CAGR	87.84%
3Y total return	563.04%
50-day SMA	$9.23
50-day SMA vs 200-day SMA	50over200
52-week high	$11.42
52-week high date	2026-10-19
52-week low	$5.25
52-week low date	2026-03-25
5Y price change	483.33%
5Y return CAGR	42.3%
5Y total return	483.33%
6M price change	74.43%
6M total return	74.43%
All-time high	$11.42
All-time high date	2026-10-19
All-time low	$0.97
All-time low date	2023-01-05
Average true range (ATR)	$0.50
Average volume	2.3M
Beta (1Y)	1.43
Beta (2Y)	1.09
Beta (5Y)	0.84
Change from 52-week high	-6.79%
Change from 52-week low	102.67%
Change from all-time high	-6.48%
Change from all-time low	1,000.4%
Change from open	1.82%
Day's gap	0%
Dollar volume	$12.8M
High price	$10.75
Low price	$10.45
Monthly RSI	72.29
Open price	$10.45
Position in 52-week range	63.33%
Premarket change	-0.38%
Premarket close	$10.45
Premarket price	$10.41
Premarket volume	5.6K
Previous close	$10.45
Price vs 150-day SMA	37.53%
Price vs 20-day SMA	3.95%
Price vs 200-day SMA	42.92%
Price vs 50-day SMA	15.68%
Relative volume	0.51
RSI	59.85
Sharpe ratio	0.46
Sharpe ratio (3Y)	1.26
Sharpe ratio (5Y)	0.77
Sortino ratio	0.73
Sortino ratio (3Y)	2.11
Sortino ratio (5Y)	1.33
Volume	1.2M
Weekly RSI	70.02
YTD price change	35.99%
YTD total return	35.99%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	176.1M
Float percentage	96.57%
Shares change (QoQ)	-2.71%
Shares change (YoY)	10.29%
Shares held by insiders	3.43%
Shares held by institutions	61.54%
Shares outstanding	182.3M
Short % of float	4.09%
Short % of shares	3.95%
Short ratio	2.5 days

Deeper analysis on XERS

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this XERS report

Is a complete XERS research report available?

No complete published report is available for Xeris Biopharma Holdings, Inc. (XERS) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Xeris Biopharma Holdings, Inc. (XERS)

Price

Financial snapshot

Fair-value bridge

Latest news · XERS

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All XERS indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on XERS

Frequently asked questions